交通医学
交通醫學
교통의학
MEDICAL JOURNAL OF COMMUNICATIONS
2014年
3期
207-209,213
,共4页
曹鑫%姜胜华%林赠华%张亚平%黄红铭%王信峰%尹红%丁佐凤%刘红%钱宇
曹鑫%薑勝華%林贈華%張亞平%黃紅銘%王信峰%尹紅%丁佐鳳%劉紅%錢宇
조흠%강성화%림증화%장아평%황홍명%왕신봉%윤홍%정좌봉%류홍%전우
淋巴瘤%SOX11基因%B细胞%淋巴结反应性增生%单克隆抗体%免疫组织化学法%流式细胞术
淋巴瘤%SOX11基因%B細胞%淋巴結反應性增生%單剋隆抗體%免疫組織化學法%流式細胞術
림파류%SOX11기인%B세포%림파결반응성증생%단극륭항체%면역조직화학법%류식세포술
lymphoma%Sox11%B cell%reactive hyperplasia of lymph node%monclonal antibody%immunohistochem-istry%flow cytometry
目的：探讨SOX11在各型B细胞非霍奇金淋巴瘤中表达的差异。方法：对B细胞非霍奇金淋巴瘤103例应用免疫组化方法检测SOX11的表达。结果：12例反应性增生中不表达SOX11，套细胞淋巴瘤21例中19例(90.5%)细胞核表达SOX11,弥漫大B细胞淋巴瘤45例中细胞核表达15例（33.3%），滤泡性淋巴瘤11例中细胞核表达4例（36.4%），伯基特淋巴瘤9例中细胞核表达2例（22.2%），小淋巴细胞淋巴瘤13例中细胞核散在弱阳性1例（7.7%），淋巴结边缘区淋巴瘤4例中细胞核中度表达1例（25.0%），SOX11在套细胞淋巴瘤的表达率和其他类型淋巴瘤比较差异有统计学意义（P<0.05）。结论：SOX11蛋白可在多种不同类型的B细胞性淋巴瘤中表达，在MCL中的表达率明显高于其它类型淋巴瘤。
目的：探討SOX11在各型B細胞非霍奇金淋巴瘤中錶達的差異。方法：對B細胞非霍奇金淋巴瘤103例應用免疫組化方法檢測SOX11的錶達。結果：12例反應性增生中不錶達SOX11，套細胞淋巴瘤21例中19例(90.5%)細胞覈錶達SOX11,瀰漫大B細胞淋巴瘤45例中細胞覈錶達15例（33.3%），濾泡性淋巴瘤11例中細胞覈錶達4例（36.4%），伯基特淋巴瘤9例中細胞覈錶達2例（22.2%），小淋巴細胞淋巴瘤13例中細胞覈散在弱暘性1例（7.7%），淋巴結邊緣區淋巴瘤4例中細胞覈中度錶達1例（25.0%），SOX11在套細胞淋巴瘤的錶達率和其他類型淋巴瘤比較差異有統計學意義（P<0.05）。結論：SOX11蛋白可在多種不同類型的B細胞性淋巴瘤中錶達，在MCL中的錶達率明顯高于其它類型淋巴瘤。
목적：탐토SOX11재각형B세포비곽기금림파류중표체적차이。방법：대B세포비곽기금림파류103례응용면역조화방법검측SOX11적표체。결과：12례반응성증생중불표체SOX11，투세포림파류21례중19례(90.5%)세포핵표체SOX11,미만대B세포림파류45례중세포핵표체15례（33.3%），려포성림파류11례중세포핵표체4례（36.4%），백기특림파류9례중세포핵표체2례（22.2%），소림파세포림파류13례중세포핵산재약양성1례（7.7%），림파결변연구림파류4례중세포핵중도표체1례（25.0%），SOX11재투세포림파류적표체솔화기타류형림파류비교차이유통계학의의（P<0.05）。결론：SOX11단백가재다충불동류형적B세포성림파류중표체，재MCL중적표체솔명현고우기타류형림파류。
Objective: To evaluate the expression of transcription factor SOX11 in B-cell non-Hodgkin lymphoma. Methods: Immunostaining of two-step EnVision method was used to detect SOX11 expression in paraffin sections of 103 patients with B-cell non-Hodgkin lymphoma. Results: In RH of lymph nodes, all cases did not express SOX11. 19 of the 21 MCL expressed strong staining of SOX11 on nuclei. 15 of the 45 (33.3%)cases of DLBCL, 4 of the 11 (36.4%) FL, 2 of the 9 (22.2%)BL, and 1 of the 4 (25.0%) N-MZL also showed weak or medium staining of SOX11 on nuclei. In 1 case of the 13 SLL, SOX11 were sparsely expressed on the nuclei of medium size cells. SOX11 nucleus expression rates were different of statistical significance among MCL and other types(P<0.001). Conclusions: (1) SOX11 could express multiple different types of lymphomas, but did not express on the reactive lymphocytes in lymphomas, which might suggest that SOX11 was related to the genesis of some types of lymphomas. (2) SOX11 expressive rates in MCL were obviously higher than those in some other types of lymphomas, especially different of statistical significance compared with SLL, which might be a crucial biomarker to differentiate CyclinD1-negative MCL from SLL.
